Abstract
I read with great interest the AJHP news article about rare disease drugs.[1][1] I applaud the Journal for its efforts in increasing awareness of rare (orphan) diseases and spotlighting the development and procurement challenges associated with rare disease (orphan) drugs.[1][1]–[3][2] In the
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
